GlassScriptPhysician profile
Petros E Carvounis
NPI 1669527537
$8,325.24
in general payments reported to CMS, 2019-2025
28 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $126 · 2021: $834 · 2022: $2,311 · 2023: $1,194 · 2024: $2,604 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,375 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,375.19 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,901.28 | 2022-2025 | Ozurdex |
| Beaver-Visitec International, INC. | $1,306.53 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,306.00 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $544.55 | 2022-2024 | Vabysmo |
| Allergan, INC. | $461.64 | 2019-2022 | |
| Oyster Point Pharma, INC. | $435.11 | 2022-2025 | Tyrvaya, Ryzumvi |
| Astellas Pharma US INC | $275.07 | 2023-2025 | Izervay |
| Notal Vision, INC. | $249.24 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $234.37 | 2024-2025 | Xdemvy |
| Alimera Sciences, INC. | $198.11 | 2021-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $183.10 | 2023-2025 | Eylea Hd, Eylea |
| Dutch Ophthalmic, USA | $181.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $168.76 | 2019-2022 | |
| Harrow Eye, LLC | $137.89 | 2023-2025 | Iheezo, Vevye |
| Biogen, INC. | $133.72 | 2022-2024 | Byooviz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $109.72 | 2020-2024 | Acthar |
| Bausch & Lomb Americas INC. | $104.41 | 2022-2023 | Vyzulta, Lotemax Sm, Prolensa |
| Apellis Pharmaceuticals, INC. | $85.19 | 2023-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $69.94 | 2022-2025 | Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.82 | 2020 | |
| Alcon Vision LLC | $46.64 | 2022-2024 | Rocklatan |
| Coherus Oncology, INC. | $28.67 | 2024 | |
| Amgen INC. | $28.40 | 2025 | Tavneos |
| Aerie Pharmaceuticals, INC. | $24.43 | 2021 | |
| Dompe US, INC. | $24.03 | 2021 | |
| Mallinckrodt Enterprises LLC | $17.01 | 2019 | |
| Biotissue Holdings INC. | $12.47 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petros Carvounis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.